ReviewFrontiers in pharmacology2026
Colchicine in atrial fibrillation: mechanisms, highlights, and current evidence.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, the global incidence of atrial fibrillation (AF) is rising, and its associated complications, such as stroke, heart failure, and thromboembolism, severely impair patients' quality of life and increase mortality and healthcare burdens. With the in-depth investigation into the mechanisms underlying the initiation and maintenance of AF, apart from classic mechanisms such as electrical remodeling, structural remodeling and autonomic nervous system dysfunction, the role of inflammatory response in the pathogenesis of AF has attracted increasing attention. Colchicine has been used as an anti-inflammatory agent for the treatment of gout and familial Mediterranean fever for many years, and it has shown favorable safety and tolerability. With continuous research, it has also demonstrated great potential in cardiovascular diseases and has been applied to the treatment and prevention of pericarditis and coronary heart disease. This article aims to summarize the mechanisms underlying colchicine's prevention of AF, discuss dosage applications for AF, outline the accumulated evidence for colchicine in preventing AF across different surgical types and disease categories, and provide an outlook on future research directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.